Literature DB >> 558726

Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases.

F Gómez, F I Reyes, C Faiman.   

Abstract

The clinical and endocrine features, and the responses to different treatment modalities, were examined in 56 patients with galactorrhea and/or hyperprolactinemia after a two month to six year follow-up period. A pituitary adenoma was diagnosed in 17 patients. A prolactin-cell adenoma was identified histologically in eight patients. Other etiologic factors were myxedema (two patients), phenothiazine ingestion (six patients) and breast manipulation (four patients). In 27 patients, including three with abnormalities of the sella turcica, no causal factor was found, and their condition was labelled as dysfunctional in origin. Symptoms were preceded by childbirth in 11 patients and by estrogen-progestin contraception in 22; pituitary adenomas were discovered in both groups in approximately the same frequency (30%) as in the over-all study group. Aside from roentgenographic studies, as well as visual field perimetry in a few cases, a serum prolactin level above 100 ng/ml was the only indicator of a pituitary prolactin-cell adenoma. Prolactin-suppression tests (L-DOPA and 2alpha-Br-ergocryptine) were found to be of no value in discriminating between tumoral and dysfunctional conditions. No significant alterations in prolactin levels occurred after water loading irrespective of basal levels or the nature of the pathologic process. Selective pituitary tumor excision (eight patients) was followed by rapid normalization of prolactin levels and disappearance of clinical abnormalities. Conversely, after pituitary irradiation (eight patients), improvement tended to be slower. Treatment of infertility in those patients without an apparent organic lesion was more successful with 2alpha-Br-ergocryptine (three of three) than with clomiphene (two of seven). Pregnancies following the administration of drugs or after surgical treatment were uneventful. Since follow-up resulted in the early diagnosis of pituitary tumors from seven to 56 months after initial investigation, and since no diagnostic tools are currently available which help to discriminate between tumoral and dysfunctional conditions before abnormalities become evident on roentgenograms, prolonged observation of these patients remains essential.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 558726     DOI: 10.1016/0002-9343(77)90866-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  Blunted response to prolactin stimulation tests and evaluation of L-dopa depression in patients with hyperprolactinemic galactorrhea.

Authors:  B L Wajchenberg; A C Lerario; B Liberman; R Marino; M C Leonardo Lancha
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

Review 2.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 3.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

4.  Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics.

Authors:  A E Pontiroli; L Falsetti
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

5.  Treatment of prolactinomas with megavoltage radiotherapy.

Authors:  A Grossman; B L Cohen; M Charlesworth; P N Plowman; L H Rees; J A Wass; A E Jones; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

6.  Present status of neurosurgery in the treatment of prolactinomas.

Authors:  R Fahlbusch; M Buchfelder
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

7.  Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).

Authors:  M Berezin; I Shimon; M Hadani
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

8.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

Authors:  S A Fine; L A Frohman
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

Review 9.  A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series.

Authors:  Somnath Mondal; Indranil Saha; Saibal Das; Abhrajit Ganguly; Debasis Das; Santanu Kumar Tripathi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

10.  Folliculostellate cells determine the susceptibility of lactotropes to estradiol's mitogenic action.

Authors:  Souichi Oomizu; Kirti Chaturvedi; Dipak K Sarkar
Journal:  Endocrinology       Date:  2003-12-11       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.